Verrica Pharmaceuticals Inc.: Form 10-Q for the period ended Jun 30, 2026
Filed with the SEC on Aug 6, 2026 and accepted by EDGAR at Aug 6, 2026, 16:37 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-04-01 to 2026-06-30 | $5.9m | us-gaap:Revenues |
| Revenue | 6 months2026-01-01 to 2026-06-30 | $10.9m | us-gaap:Revenues |
| Research and development | 3 months2026-04-01 to 2026-06-30 | $6.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2026-01-01 to 2026-06-30 | $9.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2026-04-01 to 2026-06-30 | $10.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2026-01-01 to 2026-06-30 | $20.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2026-04-01 to 2026-06-30 | −$13.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2026-01-01 to 2026-06-30 | −$22.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-04-01 to 2026-06-30 | $164.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2026-01-01 to 2026-06-30 | $324.0k | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2026-04-01 to 2026-06-30 | −$13.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2026-01-01 to 2026-06-30 | −$22.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-04-01 to 2026-06-30 | −$0.62 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2026-01-01 to 2026-06-30 | −$1.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-04-01 to 2026-06-30 | −$0.62 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2026-01-01 to 2026-06-30 | −$1.07 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-04-01 to 2026-06-30 | 21,305,025 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2026-01-01 to 2026-06-30 | 21,305,025 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2026-01-01 to 2026-06-30 | −$18.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2026-06-30 | $11.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-06-30 | $32.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2026-06-30 | $36.0m | us-gaap:Assets |
| Current liabilities | At period end2026-06-30 | $22.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-06-30 | $31.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2026-06-30 | $4.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001660334-26-000025. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.